Enfortumab vedotin-ejfv (Padcev) plus pembrolizumab (Keytruda) showed the strongest EFS, OS, and PCR associations among neoadjuvant MIBC strategies in a network meta-analysis, although perioperative design limits attribution.
Related to this article
Scammers are stealing female urologists' headshots to run AI-driven catfishing and supplement scams; in this article, 2 urologists share their experiences with this concerning trend.
Advertisement
Advertisement
Trending on Urology Times
1
Sandip Prasad, MD, on patient selection for chemoablation in LG-IR-NMIBC
2
Use of prebiopsy prostate MRI increasing across US hospitals, study finds
3
FemPulse Ring receives EU approval for overactive bladder
4
TURP, HoLEP, and the Future of Minimally Invasive BPH Therapy
5